Bryan Garnier - VICORE PHARMA (VICOR.ST) VICORE PHARMA - BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST

Report

Bryan Garnier

Eric Yoo

VICORE PHARMA - BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST

VICORE PHARMA - BUY | SEK60
Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST

KOL call details

10/10/2022 1 EN

Underlying

VICORE PHARMA

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Yoo

Other Reports on these Companies

Bryan Garnier

VICORE PHARMA | BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: Oct 12, 11 - 12:00 pm EST / 5-6 pm CEST

This event is intended for institutional clients of Bryan Garnier (BG) only. If you are a client of Bryan Garnier, please register via the link.

October 5, 2022 October 5, 2022 1 EN

Bryan Garnier

VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4

VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4 • -> COVID19 Phase 3 ATTRACT trial is a clearing event • -> We maintain a BUY rating with SEK60 TP, COVID was not in our model

September 16, 2022 September 16, 2022 1 EN

BIC forced to cut FY25 outlook after a perfect storm in Q1

We were bracing for severe turbulence in Q1 due to the weak retail environment in the US and a demanding comparison base for the rest of the world, but these headwinds proved to be more painful than expected (-10.9% LFL vs. CSSe of -7.5%), forcing the group to cut its FY25 outlook for sales (0-3% F

21h / 18m 21h / 18m 1 EN

Aurelien Deside

Aurelien Deside

Dassault Systèmes: not a great start to 2025

This morning, Dassault Systèmes published Q1 2025 results slightly below expectations for the top-line, but more significantly so on the profitability side. Revenues were up just 4%, well below consensus and the guidance midpoint, both at +5.5%, while IFRS operating income stood at 19.4%, vs 21.6%

21h / 49m 21h / 49m 1 EN

Maria Vara

Maria Vara

BONESUPPORT: Q1 revenue beats, but FX-driven EBIT miss masks solid momentum

BONESUPPORT reported a robust Q1, with net sales of SEK283.5m beating CSS SEK276m and driven by CERAMENT G sales of SEK178m in North America — well ahead of the SEK160m forecast. Gross margin remained best-in-class at 92.6%, slightly above expectations, underscoring the strength of the business mod

21h / 55m 21h / 55m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

VICORE PHARMA - BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST

VICORE PHARMA | BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: Oct 12, 11 - 12:00 pm EST / 5-6 pm CEST

VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4

BIC forced to cut FY25 outlook after a perfect storm in Q1

Dassault Systèmes: not a great start to 2025

BONESUPPORT: Q1 revenue beats, but FX-driven EBIT miss masks solid momentum

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe